Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Fiche publication
Date publication
novembre 2017
Journal
Annals of surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRIGAND Cécile
Tous les auteurs :
Mantziari S, Gronnier C, Renaud F, Duhamel A, Théreaux J, Brigand C, Carrère N, Lefevre JH, Pasquer A, Demartines N, Collet D, Meunier B, Mariette C,
Lien Pubmed
Résumé
Based on current guidelines, clinical T3N0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II). The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0 esophageal cancer patients, with subgroup analyses by histological type (squamous cell carcinoma vs adenocarcinoma) and type of neoadjuvant treatment (chemotherapy vs radiochemotherapy).
Mots clés
Adenocarcinoma, mortality, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, mortality, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Esophageal Neoplasms, mortality, Esophagectomy, Europe, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, mortality, Neoplasm Staging, Retrospective Studies, Survival Analysis, Treatment Outcome
Référence
Ann Surg. 2017 11;266(5):805-813